Rapport Therapeutics, Inc.

NasdaqGM:RAPP Stock Report

Market Cap: US$2.0b

Rapport Therapeutics Management

Management criteria checks 3/4

Rapport Therapeutics' CEO is Abe Ceesay, appointed in Feb 2023, has a tenure of 3.42 years. total yearly compensation is $6.27M, comprised of 10.4% salary and 89.6% bonuses, including company stock and options. directly owns 1.36% of the company’s shares, worth $27.35M. The average tenure of the management team and the board of directors is 2.8 years and 2.3 years respectively.

Key information

Abe Ceesay

Chief executive officer

US$6.3m

Total compensation

CEO salary percentage10.42%
CEO tenure3.4yrs
CEO ownership1.4%
Management average tenure2.8yrs
Board average tenure2.3yrs

Recent management updates

Recent updates

Analysis Article • Nov 07

We Think Rapport Therapeutics (NASDAQ:RAPP) Can Afford To Drive Business Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Seeking Alpha • Sep 08

Rapport: Surging On Phase 2 Study Win - Full Approval Unlikely Before 2028

Summary Rapport Therapeutics, Inc.'s RAP-219 delivered impressive Phase 2a results in drug-resistant focal onset seizures, driving Rapport Therapeutics' stock up over 135% and boosting investor optimism. The drug's unique mechanism, strong efficacy, and safety profile position it as a potential best-in-class therapy with blockbuster potential if approved. Despite today's surge, the path to approval is long, requiring successful Phase 3 trials, additional funding, and patience from investors until at least 2028. While long-term holders may be rewarded, I believe the current RAPP stock valuation may be ahead of fundamentals, and short-term profit-taking is likely. Read the full article on Seeking Alpha
Analysis Article • May 08

Companies Like Rapport Therapeutics (NASDAQ:RAPP) Can Afford To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Mar 31

Rapport Therapeutics: Too Early To Be Interesting

Summary Rapport Therapeutics focuses on developing specific small molecule therapies for CNS diseases, with lead candidate RAP-219 targeting focal seizure epilepsy with fewer side effects. RAP-219 selectively targets TARPγ8 in focal seizure regions, unlike pan-AMPAR drugs like Perampanel, which cause significant side effects. Phase 1 trials show RAP-219 is well-tolerated, with no sedation or motoric impairments, and Phase 2a results are expected in mid-2025. Despite promising potential, the lack of human efficacy data and an FDA hold on a key program warrant cautious observation on RAPP stock. Read the full article on Seeking Alpha
Analysis Article • Dec 07

Companies Like Rapport Therapeutics (NASDAQ:RAPP) Can Afford To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

CEO Compensation Analysis

How has Abe Ceesay's remuneration changed compared to Rapport Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$107m

Dec 31 2025US$6mUS$653k

-US$111m

Sep 30 2025n/an/a

-US$98m

Jun 30 2025n/an/a

-US$88m

Mar 31 2025n/an/a

-US$80m

Dec 31 2024US$10mUS$577k

-US$78m

Sep 30 2024n/an/a

-US$72m

Jun 30 2024n/an/a

-US$63m

Mar 31 2024n/an/a

-US$51m

Dec 31 2023US$2mUS$400k

-US$35m

Compensation vs Market: Abe's total compensation ($USD6.27M) is about average for companies of similar size in the US market ($USD5.20M).

Compensation vs Earnings: Abe's compensation has been consistent with company performance over the past year.

CEO

Abe Ceesay (48 yo)

3.4yrs
Tenure
US$6,265,174
Compensation

Mr. Abraham N. Ceesay, also known as Abe, MBA, is Director at Charles River Laboratories International Inc. Since May 20, 2025. serves as the Chief Executive Officer and President at Rapport Therapeutics,...

Leadership Team

NamePositionTenureCompensationOwnership
Steven Paul
Founder & Independent Chairman3.6yrsUS$221.86k1.09%
$ 21.8m
Abraham Ceesay
CEO, President3.4yrsUS$6.27m1.36%
$ 27.4m
Troy Ignelzi
Chief Financial Officer2.7yrsUS$2.51m0.021%
$ 420.5k
Jeffrey Sevigny
Chief Medical Officer1.3yrsUS$3.14mno data
David Bredt
Founder & Chief Scientific Officer3.5yrsno data0.82%
$ 16.5m
Cheryl Gault
Chief Operating Officer2.8yrsUS$1.78m0.30%
$ 6.0m
Karina Chmielewski
Chief Information Officer & Head of Operationsno datano datano data
Julie DiCarlo
Head of Communications & Investor Relations2.5yrsno datano data
Kathleen Wilkinson
Chief People Officer2.4yrsno datano data
Swamy Yeleswaram
Chief Development Officer3.5yrsno data0.52%
$ 10.4m
Arnold Gammaitoni
Senior Vice President of Medical Affairsno datano datano data
Gregg Keaney
Senior Vice President of CMC & Product Developmentno datano datano data
2.8yrs
Average Tenure
58yo
Average Age

Experienced Management: RAPP's management team is considered experienced (2.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Steven Paul
Founder & Independent Chairman3.6yrsUS$221.86k1.09%
$ 21.8m
Abraham Ceesay
CEO, President3.3yrsUS$6.27m1.36%
$ 27.4m
John Michael Maraganore
Independent Director2.3yrsUS$230.36k0%
$ 0
James Healy
Independent Director2.9yrsUS$235.36k0.010%
$ 202.7k
Robert Perez
Independent Director1.7yrsUS$141.93kno data
David Julius
Chair of Scientific Advisory Boardless than a yearno datano data
Allan Basbaum
Member of Scientific Advisory Boardno datano datano data
David Clapham
Member of Scientific Advisory Boardno datano datano data
Paul Silva
Independent Director1.7yrsUS$147.93kno data
Reid Huber
Director4.4yrsUS$221.86k0.043%
$ 857.7k
Wendy Young
Independent Director1.7yrsUS$136.93k0.020%
$ 399.4k
Jeffrey Noebels
Member of Scientific Advisory Boardno datano datano data
2.3yrs
Average Tenure
60.5yo
Average Age

Experienced Board: RAPP's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/10 23:15
End of Day Share Price 2026/07/10 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Rapport Therapeutics, Inc. is covered by 14 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kambiz YazdiBTIG
Jason ButlerCitizens JMP Securities, LLC
Salveen RichterGoldman Sachs